Introduction
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and joint deformation, affecting an estimated 0.3% to 1.0% of the adult population worldwide who, if left untreated, will suffer severe disability and premature mortality [@B1]. Common features of RA include monocyte infiltration, inflammation, synovial swelling, pannus formation, stiffness in the joints and articular cartilage destruction [@B2]. The etiology of RA remains unclear. However, considerable clinical data indicate that genetic factors act as markers and contribute to the development of this disease [@B3]. Indeed, genetic factors may be responsible for up to 60% of overall susceptibility to RA [@B3]. We sought to define genetic aberrations in RA, as these may lead to a better understanding of risk prediction and guide drug discovery that may lead to a more personalized approach to treatment.

Knowing how an individual\'s genetic make-up regulates disease predisposition and outcome can help us better understand aspects of disease biology and facilitate diagnosis, understand the importance of tailoring treatment to the patient, and, eventually, enable a cure or the opportunity to prevent the disease. Genetic analyses of RA pathogenesis demonstrate considerable heterogeneity among individuals and populations [@B4], [@B5]. Global genome-wide association studies (GWASs) involving large patient cohorts and typically using many hundreds of thousands of single nucleotide polymorphisms (SNPs) have contributed much understanding to RA etiology [@B6]. These GWASs have identified a number of RA-susceptibility loci, although such studies cannot directly identify the genes or genetic variants causing the disease [@B6]. Previous research has found that specific SNPs in GWAS-identified susceptibility regions are associated with RA disease progression. For instance, certain SNPs in the *interleukin* (*IL*)*-32*, *NKG2D* and *vascular endothelial growth factor* (*VEGF*) genes are known to contribute to the progression of RA [@B7]-[@B9].

High-mobility group box protein 1 (HMGB1) is a ubiquitous nuclear protein that has been discovered in mammals [@B10], [@B11]. HMGB1 contains DNA binding domains and contributes to DNA repair and the stabilization of nuclear homeostasis [@B12]. HMGB1 is usually localized in the cell nucleus and is secreted into the extracellular environment in response to different stimuli; either passively during cellular apoptosis or necrosis, or actively following inflammatory signals from activated immune cells or neuronal cells [@B13]. While previous research has confirmed the association of *HMGB1* SNPs with the susceptibility and progression of other diseases, including hepatocellular carcinoma [@B14] and uterine cervical neoplasia [@B15], little is known about the association between *HMGB1* SNPs, RA disease risk and progression. We therefore selected four *HMGB1* SNPs to investigate the association between these SNPs and RA susceptibility in healthy controls as well as disease progression in RA patients.

Materials and Methods
=====================

Participants
------------

We collected blood specimens from 232 patients (cases) who had been diagnosed with RA at Dongyang People\'s Hospital between 2014 and 2016. The control group comprised 353 healthy volunteers with no previous history of RA. We obtained written (signed) informed consent from all study participants. The study protocol was approved by the Dongyang People\'s Hospital Ethics Committee and Institutional Review Board (2015-YB002). Clinicopathologic data were collected for all patients from their medical records. We used a standardized questionnaire and searched the patients\' electronic medical records to obtain detailed clinical data on age, sex and disease duration, as well as concurrent treatment with methotrexate, prednisolone, and tumor necrosis factor (TNF) inhibitors. At baseline, serum samples were collected from all RA patients and analyzed for the presence of anti-citrullinated protein antibodies (ACPAs), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Samples were defined as ACPA-positive if anti-CCP2 titers were ≥17 IU/mL and as RF-positive if IgM RF titers were ≥30 IU/mL. Whole blood samples (3 mL) were collected from all study participants and stored at -80°C for subsequent DNA extraction.

Extraction of genomic DNA
-------------------------

We extracted genomic DNA from whole blood specimens using QIAamp DNA Blood Mini Kits (Qiagen, Valencia, CA, USA) according to the manufacturer\'s instructions. Tris-EDTA (TE buffer; (10 mM Tris-HCl, 1 mM EDTA \[ pH 7.8\]) was used to dissolve DNA then stored at -20°C [@B16], [@B17].

SNP selection
-------------

SNPs rs2249825 (3814C/G; genomic number 31,037,903) near the exon, SNP rs1412125 (-1615T/C; genomic number 31,041,595) in the promoter region, rs1360485 (3′UTR, T/C; genomic number 31,031,884) in the 3′ untranslated region and SNP rs1045411 (2262C/T; genomic number 31,033,232) in the exon selected according to the Chinese HapMap data and previous studies [@B15], [@B18]. The minor allele frequencies of these SNPs were all ≥5 %.

DNA genotyping using real-time PCR
----------------------------------

Genotyping for the *HMGB1* SNPs was performed using the TaqMan^®^ Single Nucleotide Polymorphism (SNP) Genotyping Assays (Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s instructions [@B19], [@B20].

Bioinformatic analysis
----------------------

Genotype-Tissue Expression (GTEx) data were used to identify correlations between SNPs and levels of *HMGB1* expression [@B21]. We conducted an investigation into expression quantitative trait loci (eQTLs), to determine the functional role of phenotype-associated SNPs.

Statistical Analyses
--------------------

Chi-square analysis was used to confirm that the genotype distribution of each SNP was in Hardy-Weinberg equilibrium (HWE). A Mann-Whitney *U*-test and a Fisher\'s exact test were used to compare the significance of differences in distributions of demographic characteristics between healthy controls and RA patients. The correlations between genotype frequencies, clinicopathologic characteristics and RA risk were examined using adjusted odds ratios (AORs) with 95% confidence intervals (CIs), after controlling for other covariates. Significant differences in haplotype frequencies in cases and controls were analyzed using Haploview, according to the software package [@B22]. A *p* value of \< 0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Sciences, version 9.1 (SAS Institute Inc., Cary, NC, USA).

Results
=======

All study participants were of Chinese Han ethnicity (Table [1](#T1){ref-type="table"}). Between-group differences were significant for age and gender (both *p* \< 0.001). The majority of RA patients were female (83.6%), with a mean age of 54 years, and an average RA duration of 52 months. At baseline, 60.8% were using TNF inhibitors, 45.7% were receiving methotrexate (45.7%) and 46.1% were receiving prednisolone. The majority were RF-positive (85.3%) and ACPA-positive (78.9%). To reduce possible interference of confounding variables, AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age in each comparison.

Genotype distributions for SNPs rs1360485, rs1045411, rs2249825 and rs1412125 are presented in Table [2](#T2){ref-type="table"}. In the healthy controls, all genotypic frequencies were in HWE (*p* \> 0.05). In both healthy controls and RA patients, the highest distribution frequencies for the rs1360485, rs1045411, rs2249825 and rs1412125 genes were, respectively, homozygous for T/T, homozygous for C/C, homozygous for C/C, and homozygous for T/T (Table [2](#T2){ref-type="table"}). The incidence of these polymorphisms did not differ significantly between RA patients and healthy controls (Table [2](#T2){ref-type="table"}).

However, among females, controls with one C allele in the rs1360485 were 65% less likely (AOR 0.65; 95% CI: 0.44-0.97) and those with one G allele in the rs2249825 were 58% less likely (AOR 0.58; 95% CI: 0.36-0.94) to develop RA in the future, compared with RA patients (Table [3](#T3){ref-type="table"}). These results indicate a protective effect of *HMGB1* gene polymorphisms in females.

*HMGB1* genotypes in RA patients were evaluated to clarify the role of *HMGB1* rs1360485 and rs2249825 polymorphisms in regard to RF and ACPA clinical status, RA drug consumption, as well as ESR and CRP values. No significant associations were found between any polymorphisms and clinical status, RA drug use, clinical pathologic markers or genotypes in RA patients (Table [4](#T4){ref-type="table"}).

We searched the GTEx database to investigate whether rs1360485 and rs2249825 were associated with *HMGB1* expression. Individuals carrying a genotype with the variant C at rs1360485 showed a trend for reduced expression of HMGB1, compared with the wild-type homozygous genotypes (*p* \< 0.05, Figure [1](#F1){ref-type="fig"}). In addition, those with a genotype with the variant G at rs2249825 had a slightly reduced expression of *HMGB1* (*p* = 0.06, Figure [1](#F1){ref-type="fig"}).

An analysis of distribution frequencies of *HMGB1* rs1360485, rs2249825 rs1412125 haplotypes revealed that the most common haplotype in healthy controls was T/C/T (69.12%), which was therefore selected as the reference. The C/G/T *HMGB1* haplotype significantly reduced the risk for developing RA by 0.13-fold (95% CI: 0.03-0.5, *p* \<0.05) (Table [5](#T5){ref-type="table"}). The reconstructed linkage disequilibrium plot of the four SNPs is shown in Figure [2](#F2){ref-type="fig"}. We found a haploblock in which rs1360485 and rs2249825 showed 94% linkage disequilibrium. In addition, rs1360485 and rs1412125 as well as rs2249825 and rs1412125 expressed 94% and 88% linkage disequilibrium, respectively (Figure [2](#F2){ref-type="fig"}).

Discussion
==========

RA is a complex immune-related disease, with many genetic components and environmental factors implicated in its development. Although the availability of novel therapies in the last few years have enabled an increasing number of patients with RA to achieve a state where they have only mild or no symptoms [@B23], a proportion of patients remains treatment-refractory and continues to experience progressive joint destruction, functional impairment and increased mortality. In such patients, the limitations of current RA therapies emphasize the importance of continuing to investigate the pathogenesis of RA disease and identifying new therapeutic targets. We therefore sought to determine whether genetic polymorphisms in *HMGB1*-related genes contribute to a higher susceptibility for RA. To the best of our knowledge, our study is the first to examine the distribution of the rs1360485, rs1045411, rs2249825 and rs1412125 SNPs and their possible association with RA development. We also investigated the associations of these *HMGB1* SNPs with clinical status, RA drug therapies and clinical pathologic markers, leading to a susceptibility to RA. In analyses adjusting for confounding factors, females who had one C allele in rs1360485 or one G allele in rs2249825 were at reduced risk of developing RA, by 0.65-fold (95% CI: 0.44-0.97;*p* \< 0.05) and 0.58-fold (95% CI: 0.36-0.94;*p* \< 0.05), respectively. However, concentration of HMGB1 in serum were unavailable because patients had only recently enrolled in the study. Osteoarthritis (OA) is a chronic inflammatory joints disorder associated with degradation of joints [@B24], [@B25]. Nevertheless, we did not find any report to examine *HMGB1* SNP with OA development. Furthermore, the role of *HMGB1* SNP in OA patients should also be evaluated.

HMGB1 regulates several functions with inside or outside of cell, for example immune response, DNA repair, chromatin stabilization, cell apoptosis and gene transcription *HMGB1* may play a role in the development of RA and OA [@B26], [@B27], although the evidence is uncertain as to any correlation between *HMGB1* polymorphisms and development of RA disease. In this study, we examined four *HMGB1* SNPs in 232 RA patients and in 353 healthy controls. We did not find significant differences in the incidence of RA patients with these polymorphisms compared to that of healthy controls. However, we found that in the female presence of one C allele in rs1360485 and one G allele in rs2249825 were both associated with significantly lower risks for the development of RA disease. The polymorphisms in the 3ʹ-flanking region of a gene can control gene expression [@B28]. Data from the GTEx database demonstrated that variant C at rs1360485 and variant G at rs2249825 showed a trend for reduced expression of *HMGB1*, compared with the wild-type T and C homozygous genotypes.

The linkage disequilibrium is expressed across the human genome and thus loci can be used as genetic markers to locate adjacent variants that participate to detection and treatment of disease. Haplotype analyses can provide data on the genetic contribution to disease susceptibility [@B29]. We evaluated the impacts of different haplotype combinations of three *HMGB1* SNPs (rs1360485, rs2249825 and rs1412125) upon the risk of RA disease and found that the C/G/T haplotype was associated with a low risk for RA. It is possible that the *HMGB1* C/G/T haplotype is in linkage disequilibrium with other functional polymorphisms that are responsible for susceptibility to RA.

In conclusion, our results demonstrate an association between *HMGB1* gene variants and the risk of RA. We show that the *HMGB1* rs1360485 and rs2249825 polymorphisms significantly lower the risk of RA progression Chinese Han females. This study is the first to report a correlation between *HMGB1* polymorphisms and RA risk. *HMGB1* may serve as a predictive marker for RA therapy.

This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 106-2320-B-029-002) and China Medical University (CMU106-ASIA-03).

![HMGB1 displays a significant eQTL association with rs1360485 and rs2249825 genotypes in whole blood (GTEx data set).](ijmsv14p1382g001){#F1}

![*HMGB1* pairwise linkage disequilibrium patterns. Schematic presentation of the *HMGB1* haploblock, indicating the locations of the SNP polymorphism and the pairwise linkage disequilibrium measures D\'. The measure of D\' of SNP is established according to the fraction, where a value of over 80 represents high D\'](ijmsv14p1382g002){#F2}

###### 

Characteristics of the study population

  --------------------------------------------------------------------------------------------------------------------
  Variables                      Control (n=353)\   Case (n=232)\   OR            (95% CI)   *P* Value     
                                 N (%)              N (%)                                                  
  ------------------------------ ------------------ --------------- ------------- ---------- ------------- -----------
  Age, year (mean±SD)            45.03 ± 17.39      54.38 ± 11.60                            \< 0.0001     

                                 \< 50^a^           214 (60.62)     78 (33.62)    1                        

                                 ≥ 50^a^            139 (39.38)     154 (66.38)   3.04       (2.15-4.30)   \< 0.0001

  Gender                                                                                                   

                                 female             167 (47.3)      194 (83.6)    1                        

                                 male               186 (52.7)      38 (16.4)     0.176      (0.12-0.26)   \< 0.0001

  RF                                                                                                       

                                 Negative           ND              34 (14.67)                             

                                 Positive           ND              198 (85.3)                             

  ACPA                                                                                                     

                                 Negative           ND              49 (21.1)                              

                                 Positive           ND              183 (78.9)                             

  Anti-TNF                                                                                                 

                                 Use                ND              141 (60.8)                             

                                 Non-use            ND              91 (39.2)                              

  Methotrexate                                                                                             

                                 Use                ND              106 (45.7)                             

                                 Non-use            ND              126 (54.3)                             

  Prednisolone                                                                                             

                                 Use                ND              107 (46.1)                             

                                 Non-use            ND              125 (53.9)                             

  ESR (mean±SD)                                     30.65 ± 25.06                                          

                                 \< 20^b^           ND              107 (46.1)                             

                                 ≥ 20^b^            ND              125 (53.9)                             

  CRP (mean±SD)                                     22.64 ± 80.39                                          

                                 \< 8^c^            ND              140 (61.2)                             

                                 ≥ 8^c^             ND              90 (38.8)                              

  RA duration, month (mean±SD)   ND                 52.45 ± 70.40                                          
  --------------------------------------------------------------------------------------------------------------------

N = number; OR = odds ratio; CI = confidence interval; RF = rheumatoid factor; ND = not determined; ACPA = anti-citrullinated protein antibodies; TNF = tumor necrosis factor; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; RA = rheumatoid arthritis.

^a^ Median age for entire group ^b^ normal value of ESR; ^C^ normal value of CRP.

###### 

Distribution frequencies of HMGB1 genotypes and allele frequencies of four tag SNPs in cases and controls.

  ----------------------------------------------------------------------------------------------------------------------------
  Variables   Control(n=353)\   Case(n=232)\   OR            (95% CI)   *P* Value     AOR^a^   (95% CI)   *P* Value     
              N (%)             N (%)                                                                                   
  ----------- ----------------- -------------- ------------- ---------- ------------- -------- ---------- ------------- ------
  rs1360485                                                                                                             

              TT                218 (61.8)     152 (65.5)    1                                 1                        

              CT                177 (33.1)     75 (32.3)     0.92       (0.64-1.31)   0.64     1.04       (0.69-1.57)   0.85

              CC                18 (5.1)       5 (2.2)       0.4        (0.15-1.10)   0.07     0.41       (0.13-1.27)   0.12

              TT                218 (61.76)    152 (62.52)   1                                                          1

              CT+CC             135 (38.24)    80 (34.48)    0.85       (0.60-1.20)   0.36     0.81       (0.64-1.42)   0.92

              T                 553 (78.33)    379 (81.68)   1                                 1                        

              C                 153 (21.67)    85 (18.32)    0.81       (0.60-1.09)   0.16     0.88       (0.63-1.63)   0.45

  rs1045411                                                                                                             

              CC                233 (66.0)     146 (62.9)    1                                 1                        

              CT                109 (30.9)     82 (35.4)     1.2        (0.84-1.71)   0.32     1.43       (0.95-2.15)   0.09

              TT                11 (3.1)       4 (1.7)       0.58       (0.18-1.86)   0.36     0.54       (0.14-2.10)   0.37

              CC                233 (66.01)    146 (62.93)   1                                                          1

              CT+TT             120 (33.99)    86 (37.07)    1.14       (0.81-1.62)   0.45     0.15       (0.90-2.00)   1.34

              C                 575 (81.44)    375 (80.60)   1                                 1                        

              T                 131 (18.56)    90 (19.40)    1.06       (0.78-1.42)   0.72     1.18       (0.84-1.66)   0.34

  rs2249825                                                                                                             

              CC                264 (74.8)     180 (77.6)    1                                 1                        

              CG                79 (22.4)      50 (21.5)     0.93       (0.62-1.39)   0.72     0.97       (0.61-1.54)   0.86

              GG                10 (2.8)       2 (0.9)       0.29       (0.06-1.36)   0.12     0.26       (0.05-1.44)   0.12

              CC                264 (74.79)    180 (77.59)   1                                                          1

              CG+GG             89 (25.21)     52 (22.41)    0.86       (0.58-1.27)   0.44     0.6        (0.57-1.39)   0.89

              C                 607 (85.98)    410 (88.36)   1                                 1                        

              G                 99 (14.02)     54 (11.64)    0.81       (0.57-1.15)   0.24     0.83       (0.55-1.24)   0.36

  rs1412125                                                                                                             

              TT                197 (55.8)     138 (59.5)    1                                 1                        

              CT                139 (39.4)     80 (34.5)     0.82       (058-1.17)    0.27     0.86       (0.57-1.28)   0.45

              CC                17 (4.8)       14 (6.0)      1.18       (0.56-2.46)   0.67     1.78       (0.73-4.31)   0.2

              TT                197 (55.81)    138 (59.48)   1                                                          1

              CT+CC             156 (44.19)    94 (40.52)    0.86       (0.62-1.24)   0.38     0.72       (0.63-1.37)   0.93

              T                 533 (75.50)    356 (76.72)   1                                 1                        

              C                 173 (24.50)    108 (23.28)   0.93       (0.71-1.23)   0.63     1.04       (0.75-1.42)   0.83
  ----------------------------------------------------------------------------------------------------------------------------

^a^ Logistic regression with adjustment for age, gender.

^b^ Hardy-Weinberg equilibrium test.

###### 

Association of *HMGB1* alleles and 4 tag SNPs with RA disease in the female study participants.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Variables             Control(n=167)\   Case(n=194)\    OR            (95% CI)   *P* Value     AOR^a^     (95% CI)   *P* Value     
                        N (%)             N (%)                                                                                      
  --------------------- ----------------- --------------- ------------- ---------- ------------- ---------- ---------- ------------- ----------
  Age, year (mean±SD)   41.95 ± 14.86     52.98 ± 11.55                            \< 0.0001                                         

  rs1360485                                                                                                                          

                        T                 253 (75.75)     323 (83.25)   1                                   1                        

                        C                 81 (24.25)      65 (16.75)    0.63       (0.44-0.91)   **0.01**   0.65       (0.44-0.97)   **0.04**

  rs1045411                                                                                                                          

                        C                 261 (78.14)     320 (82.47)   1                                   1                        

                        T                 73 (21.86)      68 (17.53)    0.76       (0.53-1.10)   0.14       0.86       (0.57-1.28)   0.45

  rs2249825                                                                                                                          

                        C                 280 (83.83)     348 (89.69)   1                                   1                        

                        G                 54 (16.17)      40 (10.31)    0.6        (0.38-0.92)   **0.02**   0.58       (0.36-0.94)   **0.03**

  rs1412125                                                                                                                          

                        T                 250 (74.85)     302 (77.84)   1                                   1                        

                        C                 84 (25.15)      86 (22.16)    0.85       (0.60-1.20)   0.35       0.92       (0.63-1.34)   0.66
  ---------------------------------------------------------------------------------------------------------------------------------------------

^a^ Logistic regression with adjustment for age.

###### 

Genotype frequencies of HMGB1 rs1360485/rs2249825 polymorphisms in RA patients, stratified by RA markers status.

  Variables      N (%)        N (%)          OR           (95% CI)   *P* Value     AOR^a^   (95% CI)   *P* Value     
  -------------- ------------ -------------- ------------ ---------- ------------- -------- ---------- ------------- ------
  rs1360485      TT (n=152)   CT+CC (n=80)                                                                           
  RF             Negative     25 (16.45)     9 (11.25)    1                                 1                        
                 Positive     127 (83.55)    71 (88.75)   1.55       (0.69-3.51)   0.29     1.57       (0.69-3.59)   0.29
  ACPA           Negative     34 (22.37)     15 (18.75)   1                                 1                        
                 Positive     118 (77.63)    65 (81.25)   1.25       (0.63-2.46)   0.52     1.32       (0.66-2.64)   0.44
  Anti-TNF       Negative     93 (61.18)     48 (60.00)   1                                 1                        
                 Positive     59 (38.82)     32 (40.00)   1.05       (0.60-1.83)   0.86     0.95       (0.54-1.69)   0.87
  Methotrexate   Negative     69 (45.39)     37 (46.25)   1                                 1                        
                 Positive     83 (54.61)     43 (43.75)   0.97       (0.56-1.66)   0.9      0.98       (0.56-1.73)   0.94
  Prednisolone   Negative     68 (44.74)     39 (48.75)   1                                 1                        
                 Positive     84 (55.26)     41 (51.25)   0.52       (0.50-1.46)   0.56     0.91       (0.53-1.59)   0.75
  ESR            \< 20^b^     66 (43.42)     41 (51.25)   1                                 1                        
                 ≥ 20^b^      86 (56.58)     39 (48.75)   0.73       (0.42-1.26)   0.26     0.78       (0.45-1.35)   0.37
  CRP            \< 8^c^      93 (61.18)     49 (61.25)   1                                 1                        
                 ≥ 8^c^       59 (38.82)     31 (38.75)   0.99       (0.57-1.74)   0.99     0.97       (0.55-1.71)   0.91
  rs2249825      CC (n=180)   CG+GG (n=52)                                                                           
  RF             Negative     26 (14.44)     8 (15.38)    1                                 1                        
                 Positive     154 (85.56)    44 (84.62)   0.93       (0.39-2.20)   0.87     0.9        (0.38-2.15)   0.81
  ACPA           Negative     41 (22.78)     8 (15.38)    1                                 1                        
                 Positive     139 (77.22)    44 (84.62)   1.62       (0.71-3.72)   0.25     1.81       (0.78-4.23)   0.17
  Anti-TNF       Negative     109 (60.56)    32 (61.54)   1                                 1                        
                 Positive     71 (39.44)     20 (38.46)   0.96       (0.51-1.81)   0.9      0.93       (0.48-1.78)   0.82
  Methotrexate   Negative     81 (45.00)     25 (48.08)   1                                 1                        
                 Positive     99 (55.00)     27 (51.92)   0.88       (0.48-1.64)   0.69     1.01       (0.53-1.92)   0.99
  Prednisolone   Negative     84 (46.67)     23 (44.23)   1                                 1                        
                 Positive     96 (53.33)     29 (55.77)   1.1        (0.59-2.05)   0.76     1.14       (0.60-2.14)   0.69
  ESR            \< 20^b^     80 (44.44)     27 (51.92)   1                                 1                        
                 ≥ 20^b^      100 (55.56)    25 (48.08)   0.74       (0.40-1.37)   0.34     0.77       (0.41-1.44)   0.42
  CRP            \< 8^c^      113 (62.78)    29 (55.77)   1                                 1                        
                 ≥ 8^c^       67 (37.22)     23 (44.23)   1.34       (0.75-2.50)   0.36     1.26       (0.67-2.38)   0.48

\*RF= rheumatoid factor; ACPA= anti-citrullinated protein antibodies; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein;

^a^ Logistic regression with adjustment for age and gender. ^b^ normal value of ESR ^C^ normal value of CRP

###### 

HMGB1 rs1360485/rs2249825/rs1412125 haplotype frequencies and the association with risk of RA.

  -----------------------------------------------------------------------------------------------------------------------------------
  Variables   \           \           Control\      Case\         OR     (95% CI)      *P* Value   AOR^a^   (95% CI)      *P* Value
                                      (n=353)\      (n=232)\                                                              
                                      N (%)         N (%)                                                                 
  ----------- ----------- ----------- ------------- ------------- ------ ------------- ----------- -------- ------------- -----------
  rs1360485   rs2249825   rs1412125                                                                                       

  T           C           T           488 (69.12)   328 (70.69)   1                                1                      

  T           C           C           61 (8.64)     49 (10.56)    1.2    (0.80-1.79)   0.38        1.07     (0.68-1.69)   0.78

  T           G           T           2 (0.28)      1 (0.22)      0.74   (0.07-8.24)   0.81        0.3      (0.03-3.38)   0.33

  T           G           C           2 (0.28)      1 (0.22)      0.74   (0.07-8.24)   0.81        0.62     (0.04-9.65)   0.73

  C           C           T           32 (4.53)     24 (5.17)     1.12   (0.65-1.93)   0.69        1.15     (0.61-2.16)   0.67

  C           C           C           26 (3.68)     9 (1.94)      0.52   (0.24-1.11)   0.09        0.61     (0.25-1.46)   0.26

  C           G           T           11 (1.56)     3 (0.65)      0.41   (0.11-1.47)   0.17        0.13     (0.03-0.50)   **0.003**

  C           G           C           84 (11.9)     49 (10.56)    0.89   (0.59-1.27)   0.46        1.09     (0.67-1.69)   0.71
  -----------------------------------------------------------------------------------------------------------------------------------
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